Your Premier Source for AI-Powered Animal Health Business Insights
SOCIAL MEDIA LINKS
Your Premier Source for AI-Powered Animal Health Business Insights
SOCIAL MEDIA LINKS
In a strategic expansion move this July, Merck Animal Health (known internationally as MSD Animal Health) announced the completion of its acquisition of Elanco’s aqua business, while also securing key FDA approvals for both companion and livestock products. These developments signal a broader shift in how Merck is positioning itself across the animal health value chain—from aquaculture to household pets to poultry.
The acquisition of Elanco’s aqua portfolio expands MSD AH’s presence in aquatic animal health, giving it access to a comprehensive product suite of vaccines, anti-parasitics, and nutritional health solutions for farmed fish, especially salmonids. This move reflects the company’s focus on long-cycle, biologics-based animal care solutions, and positions it strongly in the global aquaculture sector, which continues to grow rapidly and now accounts for more than 50% of fish consumed globally according to FAO figures.
Aquaculture is also a key area for innovation, particularly in disease management and vaccination. As farmed fish populations increase, disease pressure is intensifying, driving demand for solutions that balance productivity with animal welfare and food safety. By strengthening its R&D and commercial capabilities in this space, MSD AH is preparing for long-term value capture in a market projected to exceed $13 billion globally by 2027.
In parallel, MSD AH announced three FDA milestones:
• BRAVECTO® QUANTUM, a 12-month injectable parasiticide for dogs, was approved as the latest in its premium BRAVECTO line. This is the first injectable parasiticide of its kind offering full-year protection with a single vet-administered dose. It answers growing consumer demand for convenience and compliance, especially in urban pet owner segments.
• EXZOLT™, a systemic treatment for poultry red mites, received U.S. approval. Already available in Europe, it’s a much-needed option in poultry production, particularly in cage-free or aviary systems where mite control is challenging. Red mite infestations cause stress, anemia, and productivity losses—making EXZOLT a high-impact intervention in layer operations.
• MSD AH also received a positive opinion in Europe for new Nobivac® vaccines, expanding its companion animal immunization portfolio.
From a business standpoint, Merck’s moves illustrate a clear strategy: layering high-margin, innovation-driven products across species categories. The BRAVECTO injectable strengthens MSD AH’s position in the premium pet space, where owners are willing to pay for convenience and peace of mind. EXZOLT addresses pain points in poultry welfare and performance, while the aqua acquisition supports the company’s growth in sustainable protein markets.
Each of these products also reflects MSD AH’s commitment to data-backed health outcomes, often supported by digital tracking tools and on-farm diagnostics, which adds another layer of economic value and customer stickiness.
For the broader animal health industry, the message is clear: growth is coming from species diversification and innovation depth. Companies that solve specific health problems—whether parasites in layers, dogs, or salmon—stand to win both market share and loyalty.
🔗 Resource: MSD Animal Health (Merck Animal Health in U.S. and Canada) corporate website.
All rights reserved to The Animal Economics © Copyright 2026 | Web design & implementation: PAQ Consultancy
This website uses cookies. For details, please see our privacy policy. By clicking on the relevant button or any other element of the page, you consent to the use of cookies.